Topics

Latest "Acetylon Pharmaceuticals" News Stories

03:52 EST 11th December 2019 | BioPortfolio

Here are the most relevant search results for "Acetylon Pharmaceuticals" found in our extensive news archives from over 250 global news sources.

More Information about Acetylon Pharmaceuticals on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Acetylon Pharmaceuticals for you to read. Along with our medical data and news we also list Acetylon Pharmaceuticals Clinical Trials, which are updated daily. BioPortfolio also has a large database of Acetylon Pharmaceuticals Companies for you to search.

Showing "Acetylon Pharmaceuticals" News Articles 1–25 of 5,300+

Relevant

Global Histone Deacetylase 2 Market Data Survey Report 2025 [Report Updated: 01011970] Prices from USD $1320

SummaryThe global Histone Deacetylase 2 market will reach Volume Million USD in 2018 with CAGR xx% 20182025. The main contents of the report including:Global market size and forecastRegional market size, production data and export importKey manufacturers manufacturing sites, capacity and production, product specifications etc.Major ApplicationMajor TypeKey manufacturers are included based on manu...


Global Histone Deacetylase 2 Market Research Report 20122024 [Published by HeyReport] Prices from USD $2110

SummaryThe global Histone Deacetylase 2 market will reach xxx Million USD in 2019 with CAGR xx% 20192024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the report describes...

Global Histone Deacetylase 2 Market Research Report 20122024 [Report Updated: 24052019] Prices from USD $1857

SummaryThe global Histone Deacetylase 2 market will reach xxx Million USD in 2019 with CAGR xx% 20192024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the report describes...


Global Histone Deacetylase 2 Market Research Report 20122024 [Report Updated: 24052019] Prices from USD $2110

SummaryThe global Histone Deacetylase 2 market will reach xxx Million USD in 2019 with CAGR xx% 20192024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the report describes...

FDA approves nine generic versions of Pfizer's Lyrica

The FDA has given its approval to the first generic versions of Pfizer’s Lyrica (pregabalin), it has emerged, giving the commercial green light to not one, but nine different analogue therapies. The US regulator awarded marketing approval to generic products from Teva, Dr Reddy’s Laboratories, Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, InvaGen Pharmaceuticals, MSN Lab...

Belgium’s UCB to buy Ra Pharmaceuticals for $2.1bn

Under the deal, Ra Pharmaceuticals shareholders will secure $48 in cash for each of its share at closing. Based in Cambridge of Massachusetts, Ra Pharma uses an advanced The post Belgium’s UCB to buy Ra Pharmaceuticals for $2.1bn appeared first on Pharmaceutical Business review.

Belgium’s UCB to buy Ra Pharmaceuticals for $ 2.1bn

Under the deal, Ra Pharmaceuticals shareholders will secure $48 in cash for each of its share at closing. Based in Cambridge of Massachusetts, Ra Pharma uses an advanced The post Belgium’s UCB to buy Ra Pharmaceuticals for $ 2.1bn appeared first on Pharmaceutical Business review.

COSMO Pharmaceuticals N.V.: Cosmo Pharmaceuticals:; FDA-Zulassung für IND-Antrag von CB-03-10

Cosmo Pharmaceuticals:FDA-Zulassung für IND-Antrag von CB-03-10 Dublin - 7. Mai 2019 - Cosmo Pharmaceuticals NV (SIX: COPN) gab heute bekannt, dass die US-amerikanische Arzneimittelbehörde (FDA) d...

pressrelations.de/Clinuvel Pharmaceuticals - -2-

DJ pressrelations.de/Clinuvel Pharmaceuticals - Tolle BiotechaktieClinuvel Pharmaceuticals - Tolle Biotechaktie Das australische Pharmaunternemen Clinuvel Pharmaceuticals entwickelt und kommerziali...

GW Pharmaceuticals: Überzeugende Quartalszahlen

Kulmbach (www.aktiencheck.de) - GW Pharmaceuticals-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär", nimmt in einer aktuellen Aktienanalyse die GW Pharmaceuticals...

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON, MA / ACCESSWIRE / August 29, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin tech...

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Appoints Dr. Maya Said to its Board of Directors

BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin tech...

Sobi to buy Dova Pharmaceuticals in £915m deal

The deal to acquire Dova Pharmaceuticals includes an upfront payment of $27.50 (£22.35) per share in cash, as well as one non-tradeable contingent value right (CVR). Dova Pharmaceuticals The post Sobi to buy Dova Pharmaceuticals in £915m deal appeared first on Pharmaceutical Business review.

Sobi to buy Dova Pharmaceuticals in $915m deal

The deal to acquire Dova Pharmaceuticals includes an upfront payment of $27.50 (£22.35) per share in cash, as well as one non-tradeable contingent value right (CVR). Dova Pharmaceuticals The post Sobi to buy Dova Pharmaceuticals in $915m deal appeared first on Pharmaceutical Business review.

Cannabics Pharmaceuticals Inc.: Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California

TEL AVIV, ISRAEL and BETHESDA, MD / ACCESSWIRE / May 30, 2019 / Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, t...

Adamis Pharmaceuticals Provides Update on Litigation with Belcher Pharmaceuticals

SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that Adamis and Belcher Pharmaceuticals, LLC (“Belcher”) agreed to settle all previously filed litigation between the parties, including the case filed by Adamis in the … Continue reading →

AFT Pharmaceuticals (AFT) - A licensing deal for Pascomer

Edison Investment Research - Pharmaceuticals & healthcare - AFT Pharmaceuticals: AFT Pharmaceuticals has reported a North American licensing deal for Pascomer, a topical formulation of rapamycin being developed for facial angiofibromas in tuberous sclerosis complex (TSC), to private US-based Timber Pharmaceuticals. Timber will fund clinical development and provide AFT with over US$10m in upfront, ...

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces $32 Million Private Placement and Potential Funding Mechanism for PRS-060 Co-development Opt-in

BOSTON, MA / ACCESSWIRE / November 4, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® te...

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Asthma-focused Translational Research Collaboration with the University of Pittsburgh

BOSTON, MA / ACCESSWIRE / November 15, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® t...

Telix Pharmaceuticals Limited: Telix Pharmaceuticals and Eczacibasi-Monrol Sign Manufacturing and Distribution Agreement

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) ("Telix", the "Company"), a clinical-stage biopharmaceutical company focused on ...

UCB to acquire Ra Pharmaceuticals in $2.1bn deal

Belgian biopharmaceutical firm UCB has signed a merger agreement to acquire US-based Ra Pharmaceuticals for $48 per share, totalling $2.1bn...Read More... The post UCB to acquire Ra Pharmaceuticals in $2.1bn deal appeared first on Pharmaceutical Technology.

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Present Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

BOSTON, MA / ACCESSWIRE / November 5, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® te...

Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals to Present Clinical and Scientific Updates at HEP DART 2019

EDISON, NJ / ACCESSWIRE / December 9, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disea...

Telix Pharmaceuticals Limited: Telix Pharmaceuticals and PI Medical Sign Distribution Agreement for the Netherlands

MELBOURNE, Australia and RAAMSDONKSVEER, Netherlands, July 02, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) ("Telix", the "Company"), a clinical-stage biopharmaceutical company ...

Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

EDISON, NJ / ACCESSWIRE / December 10, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver dise...


Quick Search

News Quicklinks